530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study

A Seeber; F Huemer; B Doleschal; H Taghizadeh; P Reimann; Florian Moik; Sarah Madelaine Kostmann; L Wagner; L Granitzer; M Abdel Hamid; C Bachleitner; A Amann; D Wolf; R Greil; Philipp Jost; T Winder; H Rumpold; L Weiss; A Gerger; Jakob Riedl

530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study

A Seeber
, F Huemer
, B Doleschal
, H Taghizadeh
, P Reimann
, Florian Moik
, Sarah Madelaine Kostmann
, L Wagner
, L Granitzer
, M Abdel Hamid
, C Bachleitner
, A Amann
, D Wolf
, R Greil
, Philipp Jost
, T Winder
, H Rumpold
, L Weiss
, A Gerger
, Jakob Riedl

Division of Oncology

Research output: Contribution to conference book › Conference abstract

Original language	English
Publication status	Published - 2024
Event	ESMO 2024 - Barcelona, Spain Duration: 13 Sept 2024 → 17 Sept 2024

Conference

Conference	ESMO 2024
Country/Territory	Spain
City	Barcelona
Period	13/09/24 → 17/09/24

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

302 Clinical Medicine

530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study
Seeber, A. (Author), Huemer, F. (Author), Doleschal, B. (Author), Taghizadeh, H. (Author), Reimann, P. (Author), Moik, F. (Author), Kostmann, S. M. (Author), Wagner, L. (Author), Granitzer, L. (Author), Abdel Hamid, M. (Author), Bachleitner, C. (Author), Amann, A. (Author), Wolf, D. (Author), Greil, R. (Author), Jost, P. (Author), Winder, T. (Author), Rumpold, H. (Author), Weiss, L. (Author), Gerger, A. (Author) & Riedl, J. (Author)
2024
Activity: Talk, presentation or poster › Poster

Cite this

Seeber, A., Huemer, F., Doleschal, B., Taghizadeh, H., Reimann, P., Moik, F., Kostmann, S. M., Wagner, L., Granitzer, L., Abdel Hamid, M., Bachleitner, C., Amann, A., Wolf, D., Greil, R., Jost, P., Winder, T., Rumpold, H., Weiss, L., Gerger, A., & Riedl, J. (2024). 530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study. Abstract from ESMO 2024, Barcelona, Spain.

@conference{89a4178ac19a428f8a541dc10743c2e7,

title = "530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study",

author = "A Seeber and F Huemer and B Doleschal and H Taghizadeh and P Reimann and Florian Moik and Kostmann, \{Sarah Madelaine\} and L Wagner and L Granitzer and \{Abdel Hamid\}, M and C Bachleitner and A Amann and D Wolf and R Greil and Philipp Jost and T Winder and H Rumpold and L Weiss and A Gerger and Jakob Riedl",

year = "2024",

language = "English",

note = "ESMO 2024 ; Conference date: 13-09-2024 Through 17-09-2024",

}

Seeber, A, Huemer, F, Doleschal, B, Taghizadeh, H, Reimann, P, Moik, F , Kostmann, SM, Wagner, L, Granitzer, L, Abdel Hamid, M, Bachleitner, C, Amann, A, Wolf, D, Greil, R, Jost, P, Winder, T, Rumpold, H, Weiss, L, Gerger, A & Riedl, J 2024, '530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study', ESMO 2024, Barcelona, Spain, 13/09/24 - 17/09/24.

TY - CONF

T1 - 530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study

AU - Seeber, A

AU - Huemer, F

AU - Doleschal, B

AU - Taghizadeh, H

AU - Reimann, P

AU - Moik, Florian

AU - Kostmann, Sarah Madelaine

AU - Wagner, L

AU - Granitzer, L

AU - Abdel Hamid, M

AU - Bachleitner, C

AU - Amann, A

AU - Wolf, D

AU - Greil, R

AU - Jost, Philipp

AU - Winder, T

AU - Rumpold, H

AU - Weiss, L

AU - Gerger, A

AU - Riedl, Jakob

PY - 2024

Y1 - 2024

M3 - Conference abstract

T2 - ESMO 2024

Y2 - 13 September 2024 through 17 September 2024

ER -

530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study

Conference

UN SDGs

Branches of science

Activities

530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study

Cite this